Printer Friendly

DR. SHELDON M. WOLFF JOINS GENETICS INSTITUTE BOARD

 CAMBRIDGE, Mass., April 26 /PRNewswire/ -- Genetics Institute, Inc. (MASDAQ: GENIZ) announced today that Sheldon M. Wolff, M.D. has joined its board of directors. Dr. Wolff has served as both Physician-in-Chief at New England Medical Center Hospital and as Endicott Professor and Chairman of the Department of Medicine at Tufts University School of Medicine since 1977. Since 1992, he has been President of Pratt Medical Management, Inc.
 Dr. Wolff is a graduate of the Vanderbilt University School of Medicine. He has received many awards and honors and was recently the recipient of the Bristol Award for distinguished achievement in infectious diseases from the Infectious Diseases Society of America. In addition, Dr. Wolff has served on the Editorial Boards of numerous publications.
 "We welcome Dr. Wolff's experience and expertise in the practice of clinical medicine and research and look forward to his contributions in the development of our product candidates," said Gabriel Schmergel, President and Chief Executive Officer of Genetics Institute.
 Genetics Institute (NASDAQ:GENIZ) is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The Company is currently developing five pharmaceutical products for commercialization in the U.S. Three of these products are now being tested in humans for their potential use in treating serious bone fractures, cancer, the side effects of chemotherapy and infectious disease.
 Several of the Company's early product discoveries are being developed and commercialized by marketing partners. Recombinate(tm) brand recombinant Factor VIII antihemophilic factor (rAHF) is being sold by Baxter Healthcare Corporation in the U.S., Canada and Sweden and awaits European approval. Genetics Institute manufactures the bulk drug substance used in Recombinate rAHF. Recormon(R) and Epogin(R) brands of EPO are being sold in Europe and Japan by Boehringer Mannheim, GmbH and Chugai Pharmaceutical Company, Ltd. Leucomax(R) brand GM-CSF is being sold in several major European countries by Sandoz, Ltd. and Schering- Plough Corporation and awaits U.S. approval.
 American Home Products Corporation (NYSE:AHP) holds a majority interest in Genetics Institute. AHP is a world leader in the marketing and manufacturing of prescription drugs, medical supplies, diagnostics, over-the-counter medicines and food products.
 -0- 4/26/93
 /CONTACT: Dennis Harp or Gina Price, corporate communications for Genetics Institute, 617-876-1170/
 (GENIZ AHP)


CO: Genetics Institute, Inc.; American Home Products ST: Massachusetts IN: MTC SU: PER

CH -- NE009 -- 0625 04/26/93 11:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 26, 1993
Words:401
Previous Article:BESTOP ANNOUNCES NEW AGREEMENTS WITH CAMI AUTOMOTIVE, SUZUKI MOTORS, AND EXPANDED KIA PROGRAM
Next Article:MORRISON KNUDSEN UNVEILS FIRST PASSENGER RAIL CAR BUILT AT CHICAGO'S HISTORIC PULLMAN PLANT SINCE WORLD WAR II
Topics:


Related Articles
WORLD RENOWNED RESEARCHER JAMES WILSON, M.D., PH.D., TO LEAD UNIVERSITY OF PENNSYLVANIA MEDICAL CENTER'S GENE THERAPY INITIATIVE
LAWRENCE STEIN TO JOIN GENETICS INSTITUTE AS GENERAL COUNSEL AND SENIOR VICE PRESIDENT
GENETICS INSTITUTE ANNOUNCES OFFICER CHANGES
MYRIAD GENETICS, INC. NAMES WOLFGANG HARTWIG, PH.D TO BOARD OF DIRECTORS
BENNO C. SCHMIDT RETIRES AS GENETICS INSTITUTE'S CHAIRMAN OF THE BOARD
Schering-Plough Appoints Chang Vice President, Chief Scientific Officer, of Canji Gene Therapy Unit
Acacia Biosciences Names Stewart Scherer, Ph.D. Vice President of Bioinformatics
Interleukin Genetics Expands Its Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters